Phenylarsine oxide blocks interleukin-lβ-induced activation of the nuclear transcription factor NF-kB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells

Blood

Volumn 94, Issue 8, 1999, Pages 2844-2853

  Estrov, Zeev ^a,b   Manna, Sunil K ^a   Harris, David ^a   Van, Quin ^a   Estey, Elihu H ^a   Kantarjian, Hagop M ^a   Talpaz, Moshe ^a   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENOSOBENZENE; CASPASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0032878542     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.8.2844.420k43_2844_2853     Document Type: Article

References (74)

1. Estey E: Treatment of refractory AML. Leukemia 10:932, 1996
2. Huang SL, Guo AX, Xiang Y, Wang XB, Ling HJ, Fu L: Clinical study on the treatment of APL mainly with composite indigo naturalis tablets. Chin J Hematol 16:26, 1995
3. 3 exerts dose-dependent dual effects on APL cells. Blood 89:3345, 1997
4. 3) in the treatment of acute promyelocytic leukemia: Expression and modulation of PML-RARα/ PML proteins. Blood 88:1052, 1996
5. Oetken C, von Willebrand M, Autero M, Tutu T, Andersson L, Mustelin T: Phenylarsine oxide augments tyrosine phosphorylation in hematopoietic cells. Eur J Haematol 49:208, 1992
6. Singh S, Aggarwal BB: Protein-tyrosine phosphatase inhibitors block tumor necrosis factor-dependent activation of the nuclear transcription factor NF-κB. J Biol Chem 270:10631, 1995
7. Tenen DG, Hromas R, Licht JD, Zhang D-E: Transcription factors normal myeloid development and leukemia. Blood 90:489, 1997
8. Seibenlist U, Franzoso G, Brown K: Structure regulation and function of NF-kappa B. Annu Rev Cell Biol 10:405, 1994
9. Estrov Z, Kurzrock R, Estey E, Wetzler M, Ferrajoli A, Harris D, Blake M, Gutterman JU, Talpaz M: Inhibition of acute myelogenous leukemia blast proliferation by IL-1 receptor antagonist and soluble IL-1 receptors. Blood 79:1938, 1992
10. Rambaldi A, Torcia M, Bettoni S, Vannier E, Barbui T, Shaw AR, Dinarello CA, Cozzolino F: Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. Blood 78:3248, 1991
11. Yin M, Gopal V, Banavali S, Gartside P, Preisler H: Effects of an IL-1 receptor antagonist on acute myeloid leukemic cells. Leukemia 6:898, 1992
12. Estrov Z, Black RA, Sleath PR, Harris D, Van Q, LaPushin R, Estey E, Talpaz M: Effect of interleukin-1β converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation. Blood 86:4594, 1995
13. Wang C, Curtis JE, Minden MD, McCulloch EA: Expression of retinoic acid receptor gene in myeloid leukemia cells. Leukemia 3:264, 1989
14. Papayannopoulou T, Nakamoto B, Kurachi S, Tweeddale M, Messner H: Surface antigen profile and globin phenotype of two new human erythroleukemia lines: Characterization and interpretation. Blood 72:1029, 1988
15. Estrov Z, Cohen A, Gelfand EW, Freedman MH: Synergistic antiproliferative effects on HL-60 cells: Deferoxamine enhances cytosine arabinoside methotrexate and daunorubicin cytotoxicity. Am J Pediatr Hematol Oncol 10:288, 1988
16. Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris D, Gutterman JU, Talpaz M: Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: A novel application for inhibitors of IL-1 activity. Blood 78:1476, 1991
17. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 227:680, 1970
18. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 76:4350, 1979
19. Gershoni JM, Palade GE: Protein blotting: Principles and applications. Anal Biochem 131:1, 1983
20. Schreiber E, Matthias P, Muller MM, Schaffner W: Rapid detection of octamer binding proteins with "mini-extracts" prepared from a small number of cells. Nucleic Acids Res 17:6419, 1989
21. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248, 1976
22. Chaturvedi M, Kumar A, Darnay B, Chainy GBN, Aggarwal S, Aggarwal BB: Sanguinarine (pseudochelerythrine) is a potent inhibitor of NF-kappa B activation, I-kappa B alpha phosphorylation, and degradation. J Biol Chem 272:30129, 1997
23. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493, 1992
24. Shaw G, Levy PC, LoBuglio AF: Human monocyte antibody-dependent cell-mediated cytotoxicity to tumor cells. Clin Invest 62: 1172, 1978
25. Estrov Z, Grunberger T, Chan HSL, Freedman MH: Juvenile chronic myelogenous leukemia: Characterization of the disease using cell cultures. Blood 67:1382, 1986
26. Bertoncello I, Bradley R, Watt SM: An improved negative immunomagnetic selection strategy for the purification of primitive hemopoietic cells from normal bone marrow. Exp Hematol 19:95, 1991
27. Buick RN, Till JE, McCulloch EA: A colony assay for proliferative blast cells circulating in myeloblastic leukemia. Lancet 1:862, 1977
28. Minden MD, Buick RN, McCulloch EA: Separation of blast cells and T lymphocyte progenitors in the blood of patients with acute myeloblastic leukemia. Blood 54:186, 1979
29. Freedman MH, Chan HSL, Chang L: Childhood erythroleukemia: Studies on pathogenesis using colony assays. Am J Pediatr Hematol Oncol 8:2, 1986
30. 3 and its analogs inhibit proliferation of acute myelogenous leukemia proliferation by suppressing interleukin-1β-mediated signals. J Clin Invest 100:1716, 1997
31. Dinarello CA: Biologic basis for interleukin-1 in disease. Blood 87:2095, 1996
32. Oneill LAJ: Interleukin-1 signal transduction. Int J Clin Lab Res 25:169, 1995
33. Singh S, Aggarwal BB: Protein-tyrosine phosphatase inhibitors block tumor necrosis factor-dependent activation of the nuclear transcription factor NF-κB. J Biol Chem 270:10631, 1995
34. Ozaki K, Takeda H, Iwahashi H, Kitano S, Hanezawa S: NF-κB inhibitors stimulate apoptosis of rabbit mature osteoclasts and inhibit bone resorption by these cells. FEBS Lett 410:297, 1997
35. Wang CY, Mayo MW, Baldwin AS: TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB. Science 274:784, 1996
36. Ashkenas J, Werb Z: Proteolysis and the biochemistry of life-or-death decisions. J Exp Med 183:1947, 1996
37. Martin S, Green D: Protease activation during apoptosis: Death by a thousand cuts? Cell 82:349, 1995
38. Kumar S, Harvey NL: Role of multiple cellular proteases in the execution of programmed cell death. FEBS Lett 375:169, 1995
39. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Larebnik Y: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37, 1995
40. Tewari M, Quan LT, O'Rourke K: Yama/CPP32 beta a mammalian homolog of CED-3 is a Crm-A-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase. Cell 81:801, 1995
41. Fernandes-Alnemri T, Litwack G, Alnemri ES: CPP32 a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1β-converting enzyme. J Biol Chem 269:30761, 1994
42. Datta R, Banach D, Kojima H, Talanian RV, Alnemri ES, Wong WW, Kufe DW: Activation of the CPP32 protease in apoptosis induced by 1-β-D arabinofuranosylcytosine and other DNA-damaging agents. Blood 88:1936, 1996
43. L inhibits ara-C induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res 56:4743, 1996
44. Sukuki A, Matsuzawa A, Kato M: Involvement of CPP32/Yama-like protease in CPT-11-induced death signal transduction pathway. Toxicol In Vitro 10:693, 1997
45. Nicholson DW: ICE/CED3-like proteases as therapeutic targets for the control of inappropriate apoptosis. Nat Biotechnol 14:297, 1996
46. Schlegel J, Peters I, Orrenius S, Miller DK, Thorenberg NA, Yamin TT, Nicholson DW: CPP32/apopain is a key interleukin-1 beta converting enzyme-like protease involved in FAS-mediated apoptosis. J Biol Chem 271:1841, 1996
47. Jolliffe D: A history of the use of arsenicals in man. J R Soc Med 86:287, 1993
48. Sears D: History of the treatment of chronic myelocytic leukemia. Am J Med Sci 296:85, 1998
49. Qiao YL, Taylor PR, Yao SX, Erozan YS, Luo XC, Barren MJ, Yan QY, Giffen CA, Huang SQ, Maher MM, Forman MR, Tockman MS: Risk factors and early detection of lung cancer in a cohort of Chinese tin miners. Ann Epidemiol 7:533, 1997
50. Hsueh Y, Chiou H, Huang Y, Wu W, Huang C, Yang M, Lue L, Chen G, Chen C: Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiol Biomarkers Prev 6:589, 1997
51. Johansson S, Cohen SM: Epidemiology and etiology of bladder cancer. Semin Surg Oncol 13:291, 1997
52. Cher C, Yu M, Liaw Y: Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 12:S294, 1997
53. Valberg P, Beck B, Bowers T, Keating J, Bergstrom P, Boardman P: Issues in setting health-based cleanup levels for arsenic in soil. Regul Toxicol Pharmacol 26:219, 1997
54. Sun HD, Ma L, Hu XC, Shang TD: Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integral Chin West Med 12:170, 1992
55. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354, 1997
56. Kitamura K, Yoshida H, Ohno R, Naoe T: Toxic effects of arsenic (As3+) and other metal ions on acute promyelocytic leukemia cells. Int J Hematol 65:179, 1997
57. Kitamura K, Kiyoi H, Yoshida H, Tobita T, Takeshita A, Ohno R, Naoe T: New retinoids and arsenic compounds for the treatment of refactory acute promyelocytic leukemia: Clinical and basic studies for the next generation. Cancer Chemother Pharmacol 40:S36, 1997 (suppl)
58. Koing A, Wrazel L, Warrell RP, Rivi R, Pandolfi P, Jakubowski A, Gabrilove J: Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 90:562, 1997
59. Wang ZG, Rivi R, Delva L, Konig A, Scheinberg DA, Gambacorti-Passerini C, Gabrilove JL, Warrel PR, Pandolfi PP: Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RAR alpha independent manner. Blood 92:1497, 1998
60. Oetken C, von Willebrand M, Marie-Cardine A, Pessa-Morikawa T, Stahls A, Fisher S, Mustelin T: Induction of hyperphosphorylation and activation of the p561ck protein tyrosine kinase by phenylarsine oxide, a phosphotyrosine phosphatase inhibitor. Mol Immunol 31:1295, 1994
61. Deckert M, Aussel C, Bernard A, Breittmayer J: Phenylarsine oxide and phorbol myristate acetate inhibit the CD3-induced rise of cytosolic Ca2+ in Jurkat cells by refilling internal Ca2+ stores. Biochem J 297:567, 1994
62. Bergum N: Phenylarsine oxide inhibits insulin-stimulated protein phosphatase 1 activity and GLUT-4 translocation. Am J Physiol 267:E14, 1994
63. Seibenlist U, Franzoso G, Brown K: Structure regulation and function of NF-kappa B. Annu Rev Cell Biol 10:405, 1994
64. Gini DK, Aggarwal BB: Constitutive activation of NF-κB causes resistance to apoptosis in human cutaneous T-cell lymphoma Hut-78 cells. J Biol Chem 273:14008, 1998
65. Lotem J, Peledkamar M, Groner Y, Sachs L: Cellular oxidative stress and the control of apoptosis by wild-type P53 cytotoxic compounds and cytokines. Proc Natl Acad Sci USA 93:9166, 1996
66. Brodsky RA, Bedi A, Jones RJ: Are growth factors leukemogenic? Leukemia 10:175, 1996
67. Jacobsen FW, Veiby OP, Stokke T, Jacobsen SEW: TNF-alpha bidirectionally modulates the viability of primitive murine hematopoietic progenitor cells in vitro. J Immunol 157:1193, 1996
68. Estrov Z, Kurzrock R, Talpaz M: Cytokines and their antagonists in myeloid disorders. Semin Hematol 32:220, 1995
69. Dinarello CA: Interleukin-1 and interleukin-1 antagonism. Blood 77:1627, 1991
70. Dhawan S, Singh S, Aggarwal BB: Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: Role of the nuclear transcription factor NF-κB. Eur J Immunol 27:2172, 1997
71. Jimi E, Nakamura I, Ikebe T, Akiyama S, Takahashi N: NF-κB is involved in the survival of osteoclasts promoted by interleukin-1. J Biol Chem 273:8799, 1998
72. Cohen GM: Caspases: The executioners of apoptosis. Biochem J 326:1, 1996
73. Zhang W, Ohnishi K, Shigeno K, Fujisawa S, Naito K, Nakamura S, Takeshita K, Takeshita A, Ohno R: The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 12:1383, 1998
74. Barkett M, Xue D, Horvitz HR, Gilmore TD: Phosphorylation of Iκ-B-α inhibits its cleavage by caspase CPP32 in vitro. J Biol Chem 47:29419, 1997